WHO Grants First Vaccine Authorization for Mpox in Adults
The WHO has approved the first vaccine for mpox, targeting adults aged 18 and above. Manufactured by Bavarian Nordic A/S, this two-dose vaccine addresses severe mpox outbreaks, especially in Africa, where cases are rising. Limited supply due to a single manufacturer and distribution challenges remain significant concerns. Emergency use is allowed for those under 18, given high infection rates among children, especially in Congo. Mpox spreads through direct contact, respiratory droplets, or contaminated items. The WHO and Africa CDC are working on a response plan to improve vaccine access and manage the outbreak effectively.
If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.
